Drugs / Sitagliptin
Sitagliptin
also known as
Sitagliptin phosphate · Januvia · MK-0431 · SITA · JanuviaTM · MK-0431/ONO-5435 · - sitagliptine (Januvia) · Janufer · +8 more
Small molecule targets DPP4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | JANUVIA | — | 2007-10-12 – 2020-12-04 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Janumet | — | 2009-02-18 | europa.eu ↗ |
| Approved | EU (EMA) | Januvia | — | 2007-03-20 | europa.eu ↗ |
| Approved | US (FDA) | JANUVIA | — | 2006-10-16 | fda.gov ↗ |
Trials 276 · started per year
today
US approved 2006
EU approved 2007
3
6
4
11
19
30
17
23
14
18
20
16
16
22
6
4
8
6
8
4
5
8
1
6
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Also used as a comparator or background therapy in 198 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04982705 Comparator | Jul 2021 → Nov 2022 | type 2 diabetes mellitus | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03646721 Comparator | Aug 2018 → May 2020 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02683187 Comparator | Mar 2017 → Mar 2018 | — | David D'Alessio, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT02956044 Comparator | Nov 2016 → Mar 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT02328040 Comparator | Sep 2014 → Jan 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01933672 Comparator | Oct 2013 → Mar 2014 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02749032 Comparator | Nov 2011 → Mar 2014 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 1 | NCT01054118 Comparator | Dec 2009 → Feb 2010 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00976261 Comparator | Oct 2009 → Sep 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00871507 Comparator | Apr → Jul 2009 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00842556 Comparator | Mar → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00975052 Comparator | Jan → Mar 2006 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07374328 Comparator | Jun 2025 → May 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06329882 Comparator | Mar 2024 → Mar 2026 overdue | type 2 diabetes mellitus | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01619332 Comparator | Mar 2012 → Sep 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT02689362 Comparator | Aug 2017 → Aug 2018 | type 2 diabetes mellitus | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 2 | NCT02647320 Comparator | Jan 2016 → Jan 2017 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01824264 Comparator | Nov 2015 → Nov 2016 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02513771 Comparator | Sep 2015 → Dec 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02324010 Comparator | Jul 2015 → Jan 2017 | diabetes mellitus, gastroparesis | Royal Adelaide Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02405260 Comparator | Mar 2015 → Jul 2016 | type 2 diabetes mellitus | vTv Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02202161 Comparator | Aug 2014 → Jan 2015 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02111096 Comparator | Apr 2014 → Sep 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT01475461 Comparator | Nov 2011 → Jan 2013 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01376323 Comparator | Jul 2011 → Sep 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01969357 Comparator | Jun 2011 → Apr 2012 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01338870 Comparator | Jun 2011 → Mar 2012 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01336738 Comparator | Jun 2011 → Mar 2012 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01336322 Comparator | May 2011 → Dec 2017 | prediabetes syndrome | University of Pisa | Completed | No outcome recorded |
| Phase 2 | NCT01257464 Comparator | Sep 2010 → Jun 2012 | cystic fibrosis | University of British Columbia | Terminated | No outcome recorded |
| Phase 2 | NCT01169090 Comparator | Jul 2010 → Jul 2011 | type 2 diabetes mellitus | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01059825 Comparator | Feb 2010 → Jan 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01035879 Comparator | Dec 2009 → Aug 2010 | diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01128621 Comparator | Nov 2009 → Apr 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00901979 Comparator | Apr 2009 → Jun 2010 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00947011 Comparator | Mar 2009 → Mar 2010 | glucose metabolism disease | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00881530 Comparator | Mar 2009 → May 2011 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00716092 Comparator | Jul → Nov 2008 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00642278 Comparator | Apr 2008 → Jan 2009 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00760344 Comparator | Mar 2007 → Mar 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT05219409 Comparator | Jul 2023 → Dec 2025 overdue | type 1 diabetes mellitus | University of Milan | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT00860288 Comparator | Feb 2009 → Mar 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00683735 Comparator | Feb 2009 → Dec 2012 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 2/3 | NCT00734474 Comparator | Aug 2008 → Jun 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/3 | NCT00650143 Comparator | Mar 2008 → Jun 2012 | acute myocardial infarction | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 361 trials | ||||||
| Phase 3 | NCT06560333 Comparator | Nov 2026 → Apr 2027 | type 2 diabetes mellitus | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07073768 Comparator | Jul 2025 → Dec 2026 expected | type 2 diabetes mellitus | Khyber Medical College, Peshawar | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06246799 Comparator | Nov 2024 → Apr 2029 expected | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 3 | NCT06952231 Comparator | May → Dec 2024 | diabetes mellitus | University of Lahore | Completed | No outcome recorded |
| Phase 3 | NCT06115460 Comparator | Mar 2022 → Jun 2023 | diabetic kidney disease | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04365517 Comparator | Dec 2021 → Mar 2022 | COVID-19, chronic kidney disease, type 2 diabetes mellitus | University of Milan | Unknown | No outcome recorded |
| Phase 3 | NCT04801199 Comparator | Jan 2020 → Jan 2021 | type 2 diabetes mellitus | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04161430 Comparator | Jan 2020 → Jun 2022 | type 2 diabetes mellitus | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03115112 Comparator | Oct 2017 → Oct 2018 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 3 | NCT03061214 Comparator | Aug 2017 → Mar 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03076112 Comparator | Apr 2017 → Jun 2022 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02377388 Comparator | Feb 2017 → Feb 2020 | platelet aggregation, spontaneous | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02946632 Comparator | Dec 2016 → Dec 2019 | type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02849080 Comparator | Sep 2016 → Feb 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02675335 Comparator | Mar 2016 → Mar 2017 | — | Wolfgang-Michael Franz | Withdrawn | No outcome recorded |
| Phase 3 | NCT02607865 Comparator | Feb 2016 → Feb 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02577003 Background | Nov 2015 → Nov 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02564211 Background | Oct 2015 → Mar 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03125694 Comparator | Feb 2015 → Apr 2017 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01984606 Comparator | Jan 2015 → Feb 2017 | type 2 diabetes mellitus | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 3 | NCT02254291 Comparator | Oct 2014 → Nov 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02173457 Comparator | Sep 2014 → Jan 2017 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02036515 Background | Mar 2014 → Jun 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01999218 Background | Dec 2013 → Apr 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02043054 Comparator | Dec 2013 → Sep 2017 | cardiovascular disorder, type 2 diabetes mellitus | University of Leicester | Completed | No outcome recorded |
| Phase 3 | NCT01930188 Comparator | Dec 2013 → Oct 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01834274 Comparator | Jun 2013 → Mar 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT02949193 Comparator | May 2013 → Nov 2014 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01794143 Comparator | May 2013 → Apr 2021 | type 2 diabetes mellitus | GRADE Study Group | Completed | No outcome recorded |
| Phase 3 | NCT01455870 Comparator | May 2013 → Jul 2015 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01652729 Comparator | Feb 2013 → Apr 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01455909 Comparator | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01678820 Comparator | Oct 2012 → Nov 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01549964 Comparator | Apr 2012 → Mar 2014 | glucose metabolism disease | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01545388 Background | Feb 2012 → Mar 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01038648 Comparator | Dec 2011 → Feb 2014 | type 2 diabetes mellitus | India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01529541 Comparator | May 2011 → May 2013 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01289990 Comparator | Feb 2011 → May 2013 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01242228 Background | Oct 2010 → Jun 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01177813 Comparator | Jul 2010 → Mar 2012 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01137812 Comparator | Jul 2010 → Mar 2012 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01098539 Comparator | May 2010 → Nov 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01089790 Comparator | Mar → Aug 2010 | type 2 diabetes mellitus | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT01602003 Comparator | Dec 2009 → Jun 2011 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00998686 Comparator | Nov 2009 → Oct 2011 | type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00976937 Comparator | Aug 2009 → Mar 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00958269 Comparator | Aug 2009 → Sep 2011 | impaired renal function disease, type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00838903 Comparator | Feb 2009 → Jan 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00854035 Comparator | Feb 2009 → Jun 2010 | type 2 diabetes mellitus | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00855166 Background | Feb 2009 → Jun 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00676338 Comparator | Nov 2008 → Jul 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00789191 Background | Nov 2008 → Aug 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00754988 Comparator | Oct 2008 → Mar 2011 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00770081 Comparator | Sep 2008 → Apr 2011 | impaired renal function disease, type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00666458 Comparator | Apr 2008 → Mar 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00616811 Comparator | Jan 2008 → Oct 2010 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00637273 Comparator | Jan 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00484419 Comparator | May 2007 → Apr 2008 | hyperlipidemia, type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00305604 Comparator | Mar 2006 → Mar 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00086502 Comparator | Jun 2004 → Nov 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00087516 Comparator | Jun 2004 → Jul 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 468 trials | ||||||
| Phase 4 | NCT07436663 Comparator | Feb 2026 → Nov 2027 expected | breast cancer | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07452913 Comparator | Jan → Mar 2026 overdue | type 2 diabetes mellitus | Bahria University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07108985 Background | Sep 2025 → Sep 2029 expected | hyperglycemia, type 2 diabetes mellitus | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06972732 Comparator | Jun 2025 → Oct 2026 expected | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT06759922 Comparator | Jan → Mar 2025 | type 2 diabetes mellitus | Bahria University | Completed | No outcome recorded |
| Phase 4 | NCT07531108 Comparator | Nov 2024 → Nov 2025 | type 2 diabetes mellitus | Hawler Medical University | Completed | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07711171 Comparator | Aug 2024 → Oct 2026 expected | cognitive impairment with or without cerebellar ataxia, type 2 diabetes mellitus | Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT06875193 Background | May 2024 → Dec 2025 overdue | type 2 diabetes mellitus | Dong Wha Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
| Phase 4 | NCT05667220 Comparator | Dec 2022 → Oct 2023 | type 2 diabetes mellitus | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05195944 Comparator | Oct 2022 → Dec 2026 expected | NAFLD1, diabetes mellitus, metabolic dysfunction-associated steatohepatitis | University Health Network, Toronto | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05367063 Comparator | Jan 2022 → Dec 2024 | type 2 diabetes mellitus | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05386186 Comparator | Jan 2022 → Oct 2023 | type 2 diabetes mellitus | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04298684 Comparator | Jan 2021 → Feb 2022 | benign thyroid gland neoplasm, type 2 diabetes mellitus | Centre Hospitalier Universitaire de la Guadeloupe | Unknown | No outcome recorded |
| Phase 4 | NCT03893526 Comparator | Jan 2019 → Mar 2021 | type 2 diabetes mellitus | University of Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT03738878 Comparator | Nov 2018 → Dec 2024 | hypertensive disorder | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03717688 Comparator | May 2018 → Feb 2019 | diabetes mellitus, heart failure | Nicolai Jacob Wewer Albrechtsen | Completed | No outcome recorded |
| Phase 4 | NCT03959501 Comparator | Aug 2017 → Oct 2020 | type 2 diabetes mellitus | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT03208465 Comparator | Aug 2017 → Aug 2019 | coronary artery disorder, diabetes mellitus | CHEOL WHAN LEE, M.D., Ph.D | Completed | No outcome recorded |
| Phase 4 | NCT03101930 Comparator | May 2017 → Jun 2021 | obesity disorder, prediabetes syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03014479 Comparator | Feb → Oct 2017 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02917031 Comparator | Jan 2017 → Aug 2019 | heart failure, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02920918 Comparator | Oct 2016 → Sep 2018 | systolic heart failure, type 2 diabetes mellitus | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 4 | NCT02655757 Comparator | Dec 2015 → Feb 2017 | atherosclerosis, type 2 diabetes mellitus | Li Bo | Completed | No outcome recorded |
| Phase 4 | NCT02610088 Comparator | Nov 2015 → Jul 2018 | diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02512523 Comparator | Aug 2015 → Sep 2016 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02330406 Comparator | Apr 2015 → Jan 2018 | coronary artery disorder, hyperglycemia, low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Institute for Clinical Effectiveness, Japan | Completed | No outcome recorded |
| Phase 4 | NCT02338921 Comparator | Jan 2015 → Nov 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02480465 Comparator | Jan 2015 → Dec 2016 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT02200991 Comparator | Aug 2014 → Nov 2015 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02147925 Comparator | Aug 2014 → Apr 2017 | NAFLD1 | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02072096 Background | Feb 2014 → Oct 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT02041234 Comparator | Feb 2014 → Dec 2020 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02048904 Comparator | Jan 2014 → Jan 2016 | proteinuria, type 2 diabetes mellitus | University of Missouri-Columbia | Terminated | No outcome recorded |
| Phase 4 | NCT02008682 Comparator | Dec 2013 → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01928199 Comparator | Sep 2013 → Jun 2020 | disease related to solid organ transplantation | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01859793 Comparator | Jun 2013 → Jan 2016 | atherosclerosis, type 2 diabetes mellitus | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 4 | NCT02365233 Comparator | May 2013 → Dec 2016 | NAFLD1, type 2 diabetes mellitus | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 4 | NCT01847144 Comparator | Apr 2013 → Feb 2015 | type 2 diabetes mellitus | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01785043 Comparator | Mar 2013 → Mar 2014 | type 2 diabetes mellitus | Anna Cruceta | Completed | No outcome recorded |
| Phase 4 | NCT01709305 Background | Nov 2012 → Apr 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01718093 Comparator | Oct 2012 → Dec 2015 | type 1 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01519674 Comparator | Jun 2012 → Oct 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01449747 Comparator | Dec 2011 → Aug 2014 | type 2 diabetes mellitus | The Catholic University of Korea | Completed | No outcome recorded |
| Phase 4 | NCT01530178 Comparator | Nov 2011 → Mar 2015 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01471808 Comparator | Oct 2011 → Dec 2018 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT01398592 Comparator | Jun 2011 → Jun 2012 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01269996 Comparator | May 2011 → Jul 2014 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01235819 Comparator | Nov 2010 → Sep 2011 | type 1 diabetes mellitus | Command Hospital, India | Completed | No outcome recorded |
| Phase 4 | NCT01096277 Comparator | Oct 2010 → Nov 2011 | type 2 diabetes mellitus | Hannover Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT01186562 Comparator | Aug 2010 → Jul 2015 | diabetes mellitus, pancreatitis | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT01374568 Comparator | Jul 2010 → Jul 2012 | type 2 diabetes mellitus | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 4 | NCT01193296 Comparator | Jun 2010 → Jun 2011 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01337440 Comparator | Apr 2010 → Mar 2013 | liver disorder, type 2 diabetes mellitus | Kanazawa University | Unknown | No outcome recorded |
| Phase 4 | NCT01099618 Comparator | Mar 2010 → Feb 2014 | diabetic ketoacidosis, hyperglycemia | Dawn Smiley MD | Completed | No outcome recorded |
| Phase 4 | NCT02607410 Comparator | Jan 2010 → Jan 2012 | type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01195090 Comparator | Oct 2009 → Oct 2011 | type 2 diabetes mellitus | Sung-Chen Liu | Completed | No outcome recorded |
| Phase 4 | NCT00978796 Comparator | Sep 2009 → Jan 2010 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00885638 Comparator | Aug 2009 → May 2011 | type 2 diabetes mellitus | Lund University | Completed | No outcome recorded |
| Phase 4 | NCT00957060 Comparator | Jul 2009 → Oct 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00780715 Comparator | Dec 2008 → Oct 2009 | type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00751114 Comparator | Nov 2008 → Jul 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00766441 Comparator | Aug 2008 → Oct 2009 | hypoglycemia, type 2 diabetes mellitus | University of Manchester | Terminated | No outcome recorded |
| Phase 4 | NCT00732121 Comparator | Aug 2008 → Jun 2010 | type 2 diabetes mellitus | University of Vermont | Unknown | No outcome recorded |
| Phase 4 | NCT00627744 Comparator | May 2008 → Nov 2010 | diabetes mellitus, glucose intolerance, intermediate coronary syndrome, myocardial infarction | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00666848 Comparator | Mar 2008 → Aug 2009 | hypertensive disorder, metabolic syndrome X | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00364377 Comparator | Aug 2006 → Dec 2008 | prediabetes syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07172269 Background | Sep 2024 → May 2025 | hyperlipidemia, type 2 diabetes mellitus | Mais Qais Hbeeb | Completed | No outcome recorded |
| — | NCT06187285 Comparator | Jan 2024 → May 2025 | type 2 diabetes mellitus | Medanta, The Medicity, India | Completed | No outcome recorded |
| — | NCT06147518 Comparator | Dec 2023 → Dec 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT06515652 Comparator | Sep 2023 → Jul 2024 overdue | metabolic syndrome X | Hamdard University | Recruiting | No outcome recorded |
| — | NCT05042505 Comparator | Jan 2022 → Dec 2024 | diabetes mellitus | Medanta, The Medicity, India | Completed | No outcome recorded |
| — | NCT05359341 Comparator | Sep 2020 → Sep 2021 | type 2 diabetes mellitus | Sadat City University | Completed | No outcome recorded |
| — | NCT05035849 Comparator | Jan 2020 → Apr 2021 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| — | NCT03845179 Comparator | May 2019 → Feb 2020 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT04061473 Comparator | Apr → Aug 2019 | post-surgical hypoinsulinemia | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT02879409 Background | Nov 2016 → Oct 2023 overdue | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Active not recruiting | No outcome recorded |
| — | NCT02628392 Comparator | Nov 2015 → Sep 2016 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| — | NCT02244164 Comparator | Oct 2014 → Feb 2023 | type 2 diabetes mellitus | Erasme University Hospital | Terminated | No outcome recorded |
| — | NCT01901861 Comparator | Jul 2013 → Dec 2015 | type 2 diabetes mellitus | Lund University | Completed | No outcome recorded |
| — | NCT01488279 Comparator | Sep 2012 → Jul 2014 | glucose intolerance, prediabetes syndrome | University of Vermont | Completed | No outcome recorded |
| — | NCT01512797 Comparator | Jul 2012 → Aug 2016 | type 2 diabetes mellitus | Blandine Laferrere | Completed | No outcome recorded |
| — | NCT01413542 Comparator | Nov 2011 → Jul 2013 | hypertensive disorder, type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01624116 Comparator | Aug → Sep 2011 | type 2 diabetes mellitus | Services Hospital, Lahore | Completed | No outcome recorded |
| — | NCT01349387 Background | May → Nov 2011 | type 2 diabetes mellitus | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | Completed | No outcome recorded |
| — | NCT01092663 Comparator | Mar 2010 → Jul 2011 | type 2 diabetes mellitus | KineMed | Completed | No outcome recorded |
| — | NCT01073826 Comparator | Feb 2010 → Nov 2015 | obesity disorder, type 2 diabetes mellitus | University of Zurich | Completed | No outcome recorded |
| — | NCT00881543 Comparator | Jun 2009 → Jun 2010 | type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT01140438 Comparator | Mar 2009 → Nov 2018 | diabetes mellitus | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT00747383 Comparator | Sep 2008 → Sep 2010 | type 2 diabetes mellitus | The Royal Bournemouth Hospital | Completed | No outcome recorded |
| — | NCT00659711 Comparator | Mar 2008 → Dec 2013 | type 2 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-28 | Novo Nordisk A/S | Oral semaglutid viser større reduktioner i langtidsblodsukker og vægt end sitagliptin i langtidsstudie af sikkerhed og effekt (PIONEER 3) novonordisk.com ↗ |
| 2018-06-28 | Novo Nordisk A/S | Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3 novonordisk.com ↗ |
| 2018-06-20 | Novo Nordisk A/S | Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenlignet med Victoza® og sitagliptin i PIONEER 4 og 7 novonordisk.com ↗ |
| 2018-06-20 | Novo Nordisk A/S | Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials novonordisk.com ↗ |
| 2017-12-22 | Pfizer | FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes pfizer.com ↗ |
| 2016-09-15 | Pfizer | Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes pfizer.com ↗ |
| 2012-04-06 | Novo Nordisk A/S | Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia® novonordisk.com ↗ |
| 2012-04-06 | Novo Nordisk A/S | Indlægsseddel for Victoza® i USA opdateret med data, som viser, at Victoza® virker bedre end Januvia® novonordisk.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 478 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sitagliptin | “We included 12 patients with type 2 diabetes (mean ± SD BMI 27 ± 2.6 kg/m2, HbA1c 7.1 ± 1.4% [54 ± 15 mmol/mol]) in this double-blind, placebo-controlled, crossover study to...” PMID 35796651 ↗ Oct 2022464“The aim of the present study was to determine whether sitagliptin combined with metformin as an initial treatment had non-inferior outcomes with regards to glycaemic remission...” PMID 33574913 ↗ Jan 2021 “Sitagliptin is an orally active, potent and highly selective DPP-4 inhibitor which was approved by the U.S. Food and Drug Administration (FDA) in October 2006 as a new class of...” NCT01269996 ↗ “DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured.” NCT02312427 ↗ “An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.” PMID 32362346 ↗ Apr 2020 “Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors” NCT06449235 ↗ “two fixed-dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or empagliflozin 25 mg (DW1026C2)” PMID 41883295 ↗ Mar 2026 “MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)” NCT00103857 ↗ “Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast” NCT05403281 ↗ “Sitagliptin did not change fractional lithium excretion but significantly increased total fractional sodium excretion” PMID 28550195 ↗ May 2017 “GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration” NCT03927170 ↗ “GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration” NCT03851341 ↗ “Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).” NCT03813316 ↗ “albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)” NCT01098539 ↗ “Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks” NCT04810507 ↗ “Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin” NCT03014479 ↗ “Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day” NCT05032001 ↗ “10 mg dapagliflozin/100 mg sitagliptin FDC (Treatment A) with their ICs (Treatment B)” PMID 39179458 ↗ Aug 2024 “rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.” NCT02610088 ↗ “100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet” NCT01441232 ↗ “treatment with 100 mg of sitagliptin, q.d., or placebo for 4 weeks” PMID 35551683 ↗ May 2022 “Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily” NCT02041234 ↗ “Dapagliflozin 10mg +sitagliptin 100mg combination drug” NCT06875193 ↗ “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ “subgroup 2A - addition of sitagliptin 100 mg/day” NCT03804411 ↗ “Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day” NCT02365233 ↗ “100mg sitagliptin is being used in this study.” NCT04192292 ↗ “sitagliptin (25-100mg daily)” NCT02528019 ↗ “Sitagliptin” NCT02041234 ↗ “Sitagliptin” NCT02946632 ↗ “Sitagliptin” NCT02653131 ↗ |
| Known as | - sitagliptine (Januvia) | “- sitagliptine (Januvia®)” NCT02244164 ↗ |
| Known as | Janufer | “Metformin + Janufer (Janumet)” NCT00684528 ↗ |
| Known as | Janumet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00684528 ↗ |
| Known as | Januvia | “Part A is a double-blind, randomized, parallel group, dose-ranging study, in subjects with type 2 diabetes mellitus to assess safety, tolerability, and to estimate the...” NCT00976261 ↗14“To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately...” NCT00545584 ↗ “This study tests whether a medicine in this class called sitagliptin (Januvia), which is commonly used to treat T2DM, affects markers of bone turnover in patients with T2DM.” NCT00732121 ↗ “After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.” NCT01349387 ↗ “Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type 2 Diabetes.” NCT01512797 ↗ “Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks.” NCT03659461 ↗ “1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg” NCT06560333 ↗ “Active substance: Sitagliptin Januvia™ 100 mg once daily orally during three months” NCT00627744 ↗ “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ “Sitagliptin (Januvia)” NCT00650143 ↗ “Sitagliptin (Januvia)” NCT00813228 ↗ “Sitagliptin (Januvia)” NCT07439536 ↗ |
| Known as | Januvia (brand name for sitagliptin) | “Januvia (brand name for sitagliptin)” NCT00732121 ↗ |
| Known as | Januvia (sitagliptin) | “Januvia (sitagliptin)” NCT01951339 ↗ |
| Known as | Januvia (sitaglitin) | “Januvia (sitaglitin)” NCT01006018 ↗ |
| Known as | JanuviaTM | “sitagliptin (JanuviaTM) as add-on therapy to metformin” NCT00749190 ↗1“JanuviaTM (Sitagliptin)” NCT00484419 ↗ |
| Known as | MK-0431 | “A Randomized, Placebo-Controlled, 4-period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in...” NCT00551590 ↗7“The current study was initiated to define the effects of the DPP-IV inhibitor sitagliptin (MK0431) on transplanted islet survival in nonobese diabetic (NOD) mice, an autoimmune...” PMID 19073764 ↗ Dec 2008 “A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)” NCT00975052 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks” NCT00371007 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks” NCT00482079 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days” NCT00418366 ↗ “Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally.” NCT00481663 ↗ |
| Known as | MK-0431/ONO-5435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01517321 ↗ |
| Known as | SITA | “The aim of this trial was to evaluate the efficacy and safety of the combination of once-daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA ± sulphonylurea (SU),...” PMID 21205123 ↗ Mar 20113“This post hoc analysis compared the effects of 2 GLP-1 receptor- based therapies, exenatide once weekly (EQW), a GLP-1 receptor agonist, and sitagliptin (sita), a dipeptidyl...” PMID 23748507 ↗ May 2013 “SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.” NCT02689362 ↗ “adjunctive therapy of exenatide (EXE) (5-10 microg b.i.d.) or sitagliptin (SITA)” PMID 20357372 ↗ Mar 2010 |
| Known as | Sitagliptin phosphate | “This study compares the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets versus metformin in treatment-naïve patients with type 2...” NCT06613750 ↗18“Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks” NCT00993187 ↗ “Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type 2 Diabetes.” NCT01512797 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks” NCT00371007 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks” NCT00482079 ↗ “MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days” NCT00418366 ↗ “Comparator: sitagliptin phosphate (sitagliptin)” NCT00541450 ↗ “Drug: Sitagliptin phosphate” NCT01034111 ↗ “Drug: sitagliptin phosphate” NCT00832390 ↗ “Drug: sitagliptin phosphate” NCT00833027 ↗ “Drug: Sitagliptin phosphate” NCT00363519 ↗ “Drug: sitagliptin phosphate” NCT00484419 ↗ “Drug: sitagliptin phosphate” NCT00411554 ↗ “Drug: Sitagliptin Phosphate” NCT00795275 ↗ “Drug: sitagliptin phosphate” NCT00830076 ↗ “Drug: Sitagliptin phosphate” NCT01131182 ↗ “Drug: sitagliptin phosphate” NCT00449930 ↗ “Drug: sitagliptin phosphate” NCT00545584 ↗ |
| Known as | Sitagliptin phosphate (Januvia; Merck) | “Sitagliptin phosphate (Januvia; Merck)” NCT02900417 ↗ |
| Known as | sitagliptin, Januvia | “sitagliptin, Januvia” NCT01686932 ↗ |
| Known as | sitagliptine | “- sitagliptine (Januvia®)” NCT02244164 ↗ |
| Known as | STG | “One of the currently used anti-diabetic drugs that enhances GLP-1 availability is Sitagliptin (STG).” NCT02294084 ↗ |
| Action | Inhibit | “DPP-4 inhibitor sitagliptin 100 mg/day” PMID 25633134 ↗ Jan 2015 |
| Modality | Small molecule | “a new class of anti-diabetes compounds (DPPIV-inhibitors)” NCT01093651 ↗ |
| Route | Oral | “oral tablets of sitagliptin 100 mg” NCT00086515 ↗ |
| Target | DPP4 | “prevention of hormone degradation through DPP-IV inhibition” NCT00411411 ↗ |